Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics has experienced several significant stock events in the past six months. The company entered into a binding term sheet to be acquired by Kuva Labs, Inc., but the acquisition has faced delays. Lisata Therapeutics mutually terminated its license agreement with Qilu Pharmaceutical, regaining rights for certepetide in the Greater China region. The company reported its Q3 2025 financial results, highlighting cash and investments, operating expenses, and positive data from clinical studies. Lisata Therapeutics' stock was trading at $1.86 on January 1st, 2026, and has since increased by 69.4% to $3.15 as of May 8, 2026.

Lisata Therapeutics, Inc. does not currently have established product or service demand seasonality in the traditional sense. The company's revenue for the trailing twelve months as of December 31, 2025, was $170K. However, an analysis of LSTA's historical stock price data suggests some seasonality in stock returns. May has a 38.46% probability of a positive return, while November offers the highest probability of positive returns at 63.64%.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative therapies for advanced solid tumors and other serious diseases. Their lead product candidate, certepetide, is in Phase 2 clinical studies for various solid tumors and has received Orphan Drug and Fast Track status from the FDA for pancreatic cancer, as well as Orphan Drug Designation for glioma, osteosarcoma, and cholangiocarcinoma, and Rare Pediatric Disease Designation for osteosarcoma in the U.S. The company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Lisata Therapeutics, Inc. is headquartered in Basking Ridge, New Jersey, United States. The company's operations and clinical trials for certepetide have an international scope, involving global partnerships and clinical studies. They collaborate with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Lisata Therapeutics has received positive recognition for its work in the past year. The company won the BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' for the second consecutive year, highlighting its CendR Platform® technology for enhancing tumor-targeted drug delivery. No specific negative events significantly impacting the company's brand reputation in the past year were found in the search results.

Lisata Therapeutics, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. Institutional investors own approximately 7.92% of the stock. Insiders hold a significant portion of the company's stock. Rimasia Capital Partners Manager Ltd is noted as the largest individual shareholder, owning 24.63 million shares, representing 272.72% of the company. David Mazzo, the CEO, also owns a substantial number of shares. Major institutional shareholders include Vanguard Group Inc, Renaissance Technologies Llc, BML Capital Management, LLC, Geode Capital Management, Llc, BlackRock, Inc., State Street Corp, Dimensional Fund Advisors Lp, CIBC Bancorp USA Inc., Cerity Partners LLC, and Bank Of America Corp /de/.